Latest news


Invitation to second quarter and first half year 2016 presentation

Posted on Aug 24, 2016

Oslo, 24 August 2016 – PCI Biotech invites to a presentation of the company’s second quarter and first half year 2016 report on Tuesday 30 August 2016 at Oslo Cancer Cluster Innovation Park. Time: Tuesday August 30, 09.00-10.00 hrs Venue: Jónas Einarsson aud. (2nd floor, entrance 2B), Oslo Cancer Cluster Innovation Park, Ullernchausséen 64, Oslo […]

Publication of the fimaporfin (Amphinex) first-in-man Phase I study in Lancet Oncology

Posted on Jul 28, 2016

Oslo,   28 July   2016 –   PCI   Biotech   (PCIB) a cancer focused Norwegian biopharmaceutical company, reported today that the first-in-man Phase I study with PCI Biotech’s proprietary drug fimaporfin (Amphinex(TM)) performed at University College Hospital in London in patients with various advanced solid tumours has been published in Lancet Oncology, the premier publication worldwide for original […]

PCI Biotech receives positive opinion for Orphan Drug Designation of fimaporfin for treatment of cholangiocarcinoma in EU

Posted on Jul 26, 2016

Oslo, 25 July 2016 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that it has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) for its lead product candidate, fimaporfin, for the treatment of cholangiocarcinoma (bile duct cancer). COMP’s positive opinion is subject to […]